Yujing Tan

6PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersMedical infection agents (incl. prions)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 23, 2026
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

|Dec 08, 2025
Lysine Acetyltransferase 6 in Health and Disease.

Yujing Tan, Jiani Wang, Fei Ma

|Sep 25, 2025
Novel Causal Evidence for the Role of Circulating Lipid Metabolites in Breast Cancer Risk: A Bidirectional Mendelian Randomization Analysis.

Cheng Zeng, Shuning Liu, Yuhan Wei

|Aug 16, 2025
A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.

Cheng Zeng, Yujing Tan, Zhimin Jiao

|Nov 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study.

Yujing Tan, Zexi Peng, Hanfang Jiang

|Nov 08, 2023
Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China.

Yujing Tan, Hanfang Jiang, Fei Ma

Pageof 1

Frequent Collaborators

5 joint publications

Fei Ma

2 joint publications

Cheng Zeng

1 joint publications

Hanfang Jiang

1 joint publications

Binghe Xu